Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS - it works but is it different from existing IL-17i? - appears to work well in TNFi-inadequate responders - are TNFi-IR pts immunologically different? #RNL2023 https://t.co/bHboX3Xz6M https://t.co/kCa9MbFdxs